Published in Br J Radiol on May 20, 2015
A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun (2016) 0.80
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. Oncotarget (2016) 0.77
Survival patterns of 5750 SRS-treated brain metastasis patients as a function of the number of lesions. World Neurosurg (2017) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
The cancer genome. Nature (2009) 23.13
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol (2003) 11.94
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol (2014) 8.32
The impact of O2 availability on human cancer. Nat Rev Cancer (2008) 6.84
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol (2010) 5.65
Molecular imaging in cancer. Science (2006) 5.01
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer (2012) 3.56
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Rapid-learning system for cancer care. J Clin Oncol (2010) 3.13
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
The pathobiology of mucositis. Nat Rev Cancer (2004) 2.99
Kinomics: methods for deciphering the kinome. Nat Methods (2005) 2.94
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol (2014) 2.86
Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys (2010) 2.69
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. Eur Urol (2014) 2.26
Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol (2003) 2.26
Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol (2011) 2.25
Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol (2012) 2.23
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol (2013) 2.11
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol (2005) 2.10
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol (2010) 2.09
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol (1998) 2.07
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res (2007) 2.06
An umbrella protocol for standardized data collection (SDC) in rectal cancer: a prospective uniform naming and procedure convention to support personalized medicine. Radiother Oncol (2014) 2.05
Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res (2002) 1.95
hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer (2010) 1.95
Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer (2010) 1.74
Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol (2012) 1.74
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66
The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys (2010) 1.65
'Rapid Learning health care in oncology' - an approach towards decision support systems enabling customised radiotherapy'. Radiother Oncol (2013) 1.60
Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol (2008) 1.57
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol (2007) 1.49
Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol (2010) 1.49
Interactive decision-support tool for risk-based radiation therapy plan comparison for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys (2013) 1.48
Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res (2010) 1.40
Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res (2011) 1.33
Targeted therapies: how personal should we go? Nat Rev Clin Oncol (2011) 1.31
Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res (2008) 1.30
Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene (2013) 1.24
The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control (2008) 1.23
Metcalfe's law and the biology information commons. Nat Biotechnol (2013) 1.22
Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys (2009) 1.22
miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer (2013) 1.21
Quantifying heterogeneity in human tumours using MRI and PET. Eur J Cancer (2012) 1.20
De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer (2014) 1.18
Qualification of imaging biomarkers for oncology drug development. Eur J Cancer (2012) 1.16
Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol (2010) 1.14
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol (2012) 1.14
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys (2010) 1.13
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer (2011) 1.08
DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res (2011) 1.08
A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat Genet (2014) 1.06
Interaction of radiation therapy with molecular targeted agents. J Clin Oncol (2014) 1.05
Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review. Int J Radiat Oncol Biol Phys (2013) 1.05
Molecular imaging and targeted therapies. Biochem Pharmacol (2010) 1.05
The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin Radiol (2010) 1.04
Molecular imaging biomarkers for oncology clinical trials. J Nucl Med (2014) 1.03
Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin Radiat Oncol (2010) 1.03
Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol (2011) 1.02
Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol (2013) 1.02
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res (2012) 1.02
Evidence and research in rectal cancer. Radiother Oncol (2008) 1.00
The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol (2011) 0.99
Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use? Crit Rev Oncol Hematol (2012) 0.99
Improving the efficacy of chemoradiation with targeted agents. Cancer Discov (2014) 0.97
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
Molecular radiobiology: the state of the art. J Clin Oncol (2014) 0.96
A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: a step toward individualized care and shared decision making. Radiother Oncol (2014) 0.95
The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline. Stem Cell Res Ther (2013) 0.94
Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys (2011) 0.94
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst (2013) 0.93
Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Future Oncol (2013) 0.93
Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposure. Exp Biol Med (Maywood) (2014) 0.93
Imaging in radiation oncology: a perspective. Oncologist (2010) 0.92
Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet (2013) 0.92
Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol (2010) 0.91
Global harmonization of quality assurance naming conventions in radiation therapy clinical trials. Int J Radiat Oncol Biol Phys (2014) 0.91
Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. Radiother Oncol (2011) 0.91
Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front Oncol (2014) 0.91
Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer. Clin Cancer Res (2014) 0.90
The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer. Br J Cancer (2014) 0.90
Repeated autologous bone marrow-derived mesenchymal stem cell injections improve radiation-induced proctitis in pigs. Stem Cells Transl Med (2013) 0.89
Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead. Br J Cancer (2012) 0.89
Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. Anal Bioanal Chem (2010) 0.89
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol (2011) 0.88
Personalized therapies in the cancer "omics" era. Mol Cancer (2010) 0.88
Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. Eur J Cancer (2010) 0.88
The impact of radiotherapy late effects on quality of life in gynaecological cancer patients. Br J Cancer (2009) 0.86